• 1
    Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963; i: 2389.
  • 2
    Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet 1998; 352: 799805.
  • 3
    Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79: 81329.
  • 4
    Hodgson HJF. Carcinoid tumours and the carcinoid syndrome. In: BouchierIAD, AllanRN, HodgsonHJF, KeighleyMRB, eds. Gastroenterology. Clinical Science and Practice. London: W. B. Saunders, 1993: 64358.
  • 5
    Kaplan LM. Endocrine tumours of the gastrointestinal tract and pancreas. In: WilsonJD, BraunwaldE, IsselbacherKJ, et al. , eds . Harrison's Principles and Practices of Internal Medicine. New York: McGovern Inc, 1991: 138693.
  • 6
    Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000; 62(Suppl. 1): 518.
  • 7
    Warbuton R, Keevil B. Urinary 5-hydroxyindole-acetic acid by high-performance liquid chromatography with electrochemical detection. Ann Clin Biochem 1997; 34: 4246.
  • 8
    Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumours. Analysis of prognostic factors and survival in 301 patients from a referral centre. Ann Oncol 1997; 8: 68590.
  • 9
    Rochaix P, Cordelier P, Benali N, et al. Understanding in somatostatin receptor subtypes: application for the diagnosis and treatment of digestive endocrine tumours. In: MignonM, ColombelJF, eds. Recent Advances in the Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors. Paris: John Libbey Eurotext, 1999: 30811.
  • 10
    Nilsson O, Kolby L, Wangberg B, et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 1998; 77: 6327.
  • 11
    Arnold R, Frank M, Kajdan U. Management of gastroenteropancreatic endocrine tumours: the place of somatostatin analogues. Digestion 1995; 55: 10713.
  • 12
    Harris AG. Octreotide in the treatment of disorders of the gastrointestinal system. Drug Invest 1992; 4(Suppl. 3): 154.
  • 13
    Oberg K. Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 2001; 47(Suppl. 2): 4053.
  • 14
    Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 4308.
  • 15
    Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and alpha-interferon: effect on tumour growth in metastatic endocrine gastroenteropancreatic tumours. Am J Gastroenterol 1999; 94: 13817.
  • 16
    Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: pharmacokinetics, pharmacodynamics, efficacy and tolerability in acromegalic patients. Metabolism 1995; 44: 1826.
  • 17
    Kuhn JM, Legrand A, Ruiz JM, et al. Pharmacokinetic and pharmacodynamic properties of a long acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 1994; 382: 139.
  • 18
    Larsson G. Quality of Life in Patients with Endocrine Gastrointestinal Tumours. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 989. Uppsala: Acta Universitatis Upsaliensis, 2001.
  • 19
    Tomassetti P, Migliori M, Corinaldesi R, et al. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000; 14: 55760.
  • 20
    Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17: 6006.
  • 21
    Wahid ST, Marbach P, Stolz B, et al. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST Analogues. Eur J Endocrinol 2002; 146: 295302.
  • 22
    Kaal A, Orskov H, Nielsen S, et al. Occurrence and effects of octreotide antibodies during nasal, subcutaneous and slow release intramuscular treatment. Eur J Endocrinol 2000; 143: 35361.
  • 23
    Weckbecker G, Liu R, Tolcsvai L, et al. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 1992; 52: 49738.
  • 24
    Rauly I, Saint-Laurent N, Delesque N, et al. Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells. J Clin Invest 1996; 97: 187483.
  • 25
    Cattaneo MG, Amoroso D, Gussoni G, Sanguini AM, Vicentini LM. A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines. FEBS Lett 1996; 397(2–3): 1648.
  • 26
    Leong WL, Pasieka JL. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 2002; 79: 1807.
  • 27
    Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 1989; 34(3 Suppl.): 14S27S.
  • 28
    Jansen ET, Oberg K. Long term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993; 32: 2259.
  • 29
    Gorden P, Comi RJ, Maton PN, Go VL. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110: 3550.
  • 30
    Oberg K, Norheim I, Theodorsson E. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol 1991; 30: 5037.
  • 31
    Bax ND, Woods HF, Batchelor A, Jennings M. Octreotide therapy in carcinoid disease. Anticancer Drugs 1996; 7(Suppl. 1): 1722.
  • 32
    Caplin ME, Mielcarek W, Buscombe JR, et al. Toxicity of high-activity 111In-octreotide therapy in patients with disseminated neuroendocrine tumours. Nucl Med Commun 2000; 21: 97102.